

Deep Brain Stimulation (DBS) of patients with Parkinson's disease (PD).

Scandinavia Movement Disorder Society ScandModis consensus document March 2014

Background

Patients with Parkinson's disease, who no longer can be improved by optimising the oral medical treatment, have shown significant benefits from treatment with DBS. DBS has been shown to improve motor function, reduce tremor, motor fluctuations and dyskinesias, decrease use of medication and increase Quality of Life (see reference 1. and references herein). There is a tendency to operate patients at an earlier time of disease than before.

Criteria for referral to a specialised Movement Disorder Centre for possible DBS

Patients with levodopa responsive Parkinson's disease

Preferably with a duration of Parkinson's disease > 5 years

**Moderate to severe on-off motor fluctuations

and/or

**Moderate to severe dyskinesias

and/or

Medical refractory **moderate to severe tremor

** Defined as moderate to severe impact on quality of life

*Patients with tremor dominated PD can be treated with VIM DBS also >75 years of age

Exclusion criteria

Dementia

Significant medical resistant psychiatric disease (e.g. severe depression)

Significant medical conditions with limited life expectancy

Conditions that prevent surgery or MRI

Patient eligible for DBS

Patient eligibility for DBS is determined at the Movement Disorder Centre after:

Brain imaging

Neuropsychological assessment of cognitive function and psychiatric symptoms

Levodopa challenge test

Cardiac pacemaker is not a contraindication for DBS

It is not always necessary for the patient to be awake during surgery

It is not always necessary to remove all hair

Expected outcome of DBS treatment

Expected outcome corresponds to the effect of an optimal levodopa dosage on the motor symptoms

Tremor reduction

Significant reduction of motor fluctuations

Decreased use of medication depending on surgical target, see below

Significant reduction of dyskinesias

Levodopa unresponsive symptoms like

- Axial symptoms as postural instability

- Freezing of gait

- Dysarthria

will not improve

Surgery in Parkinson's disease

Target

- The subthalamic nucleus (STN) to treat the cardinal symptoms tremor, rigidity and hypokinesia and reduce motor fluctuations

- The internal part of globus pallidus (GPi) is an alternative target to treat cardinal symptoms and especially dyskinesias, however often results in less reduction of medication

- The ventral intermediate nucleus of thalamus (VIM) to treat tremor only

The electrodes are implanted bilaterally and connected to a subcutaneous lead and impulse generator (IPG) localised beneath the clavicle

Each electrode has four contacts and stimulation contact and parameters are adjusted by computer telemetry

Surgical complications

Intracranial hemorrhage (appr. ½ -1 %)

Infection

Side effects

Worsening of dysarthria

Sometimes worsening of gait and balance especially patients > 65 years of age

Eyelid apraxia

Dystonia

Psychiatric symptoms (usually transient, treatable and potentially preventable) (7,9)

- Confusion

- Depression

- Mania

- Psychosis

- Apathy

- Increased risk of suicide

Neuropsychological symptoms

- Reduced verbal fluency

Hardware complications

Patient management and follow-up

During the first 3-6 months frequent controls in the outpatient clinic to adjust stimulation parameters and medication to obtain maximum effect of stimulation

Shared control (referral neurologist and DBS centre) of symptoms and disease development and stimulation effect

Battery replacement every 3-4 years

Rechargeable battery available.

DBS is in general a contraindication for MRI. However MRI can be performed at the DBS centre if the MRI/neurostimulator guidelines elaborated by the manufacturer are followed

Diathermy including shortwave diathermy, microwave diathermy or therapeutic ultrasound diathermy are contraindicated

It is safe, however, to perform diagnostic ultrasound examination in a patient with DBS
In case of surgery in patients with DBS monopolar electrocoagulation should be avoided. Bipolar is recommended.

If a patient with DBS needs examination by ECG, EEG or EMG the DBS can be temporarily switched off during the procedure to avoid disturbance of the examination.

References

1. Ardouin C et al. Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients. *Ann Neurol* 1999;46:217-223.
2. Castelli L et al. Chronic deep brain stimulation of the subthalamic nucleus for Parkinson's disease: effects on cognition, mood, anxiety and personality traits. *Eur Neurol* 2006;55:136-144.
3. Deuschl G, Schade-Brittinger C, Krack P et al. A randomized trial of deep-brain stimulation for Parkinson's disease. *NEJM* 2006;355:896-908
4. Deuschl G et al. Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: Concept and standards of the EARLYSTIM-study. *Parkinsonism Relat Disord* 2013;19(1):56-61.
5. Schuepbach WMM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L,....and Deuschl G, for the EARLYSTIM Study Group. Neurostimulation for Parkinson's Disease with Early Motor Complications. *N Engl J Med* 2013;368:610-22.
6. Houeto JL, Mesnage V, Mallet L et al. Behavioral disorders, Parkinson's disease, and subthalamic stimulation. *JNNP* 2002;72:701-707
7. Jahanshahi M et al. The impact of deep brain stimulation on executive function in Parkinson's disease. *Brain* 2000;123:1142-1154.
8. Krack P, Batir A, Van Blercom N et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. *NEJM* 2003;349:1925-1934
9. Castrioto A et al. Ten-year outcome of subthalamic stimulation in Parkinson's disease: a blinded evaluation. *Arch Neurol* 2011;68:1550-1556.
10. Voon V et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. *Brain* 2008;131:2720-2728.
11. Moro E et al. A decision tool to support appropriate referral for deep brain stimulation in Parkinson's disease. *J Neurol* 2009;256:83-88 (and references herein).
12. Rusmann H et al. Subthalamic nucleus deep brain stimulation in Parkinson's disease over age 70 years. *Neurology* 2004;63:1952-1954.
13. The deep-brain stimulation for Parkinson's disease study group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. *NEJM* 2001;345:956-963
14. Volkmann J, Albanese A, Kulisevsky J et al. Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease. *Mov Disord* 2009;24:1154-1161

15. Voon V, Kubu C, Krack P et al. Deep brain stimulation: neuropsychological and neuropsychiatric issues. *Mov Disord* 2006;21(suppl 14):S305-S326
16. Weaver FM, Follett K, Stern M et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. *JAMA* 2009;301:63-73
17. Witt K, Daniels C, Reiff J et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. *Lancet Neurol* 2008;7:605-624
18. Østergaard K, Sunde NA, Dupont E. Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations. *Mov Disord* 2002;17: 693-700
19. Østergaard K and Sunde N. Evolution of Parkinson's disease during four years of bilateral stimulation of the subthalamic nucleus. *Mov Disord* 2006;21:624-631